EFFICACY AND SAFETY OF SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS IN LONG-LIVED PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION

Abstract

Heart failure with preserved ejection fraction (HFpEF) is one of the most common forms of heart failure in the elderly. In the context of global population aging, the importance of this condition is growing, especially among the oldest-old patients (≥90 years), who increasingly require inpatient care However, individuals in this age group have traditionally been excluded from most large randomized clinical trials (RCTs), leading to a lack of evidence-based data specifically for this population [3]. The use of empagliflozin and dapagliflozin has shown a significant reduction in the risk of heart failure-related hospitalizations and improved prognosis, regardless of the presence of diabetes mellitus (DM). However, patients aged ≥90 years were minimally represented in these RCTs, making it difficult to directly apply these findings to the oldest-old population. Therefore, a systematic analysis of current data on the efficacy and safety of SGLT2i in this age group is necessary to optimize treatment and improve outcomes while considering geriatric characteristics. Key words: heart failure with preserved ejection fraction (HFpEF), elderly patients, oldest old, sodium-glucose cotransporter 2 inhibitors (SGLT2i), empagliflozin, dapagliflozin, efficacy, safety, geriatrics, randomized clinical trials (RCTs).